Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL17 first-line CLL phase 3 trial of ibrutinib versus fixed-duration venetoclax combinations
2022-500439-35-00Phase 3Authorised
- Sponsor
- University of Cologne
- Start
- Feb 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ibrutinib monotherapy, Fixed-duration venetoclax plus obinutuzumab and Fixed-duration venetoclax plus ibrutinib (3 arms). Primary endpoint: Progression-free survival. Planned start Feb 2021; status: authorised.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-500439-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500439-35-00.